Evaluating resminostat for patients with relapsed or refractory Hodgkin’s lymphoma

This study evaluated the safety and effectiveness of resminostat in heavily pre-treated patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that resminostat was effective and well-tolerated in these patients.

Histone deacetylase inhibitors (HDIs) are a type of biological therapy. HDIs interfere with the action of histone deacetylases (HDACs). These are proteins that control many important functions that cells need to survive. Mutations in HDAC genes have been linked to cancer development. As a result, HDACs are considered promising targets for cancer therapy.

HDIs have been shown to be effective in patients with relapsed or refractory HL. Resminostat is a new HDI. The safety and effectiveness of resminostat in patients with relapsed or refractory HL remains under investigation.

his study involved 37 heavily pre-treated patients with relapsed or refractory HL. All patients received resminostat treatment. 59% of patients had received 5 or more prior lines of therapy.

Overall, 34% of patients responded to treatment. 69% of patients had tumor shrinkage. For all patients, the average progression-free survival (time from treatment until tumor grows or spreads) was 2.3 months. The average overall survival (time from treatment until death from any cause) was 12.5 months. Patients who responded to treatment had a much longer overall survival compared to patients who had disease progression (18.0 months vs. 9.6 months).

Overall, 94.6% of patients reported side effects. Most were mild or moderate. The most common side effects reported were nausea (60%), vomiting (54%) and anemia (30%). 13.5% of patients had dose reductions due to side effects.

This study concluded that resminostat showed promising activity in patients with relapsed and refractory HL.

This study was a phase 2 study, with a small number of patients. This means that further studies need to be done to determine the safety and efficacy of this drug in the treatment of relapsed or refractory Hodgkin’s lymphoma.